Compare Agilent Technologies Inc (A) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Zeta Global Holdings Corp — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.22B), while Zeta Global Holdings Corp trades at $28.27 (market cap $7.32B). The key difference: Agilent Technologies Inc is far larger — about 5.8× Zeta Global Holdings Corp's market cap, and Agilent Technologies Inc pays a 0.68% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| A | ZETA | |
|---|---|---|
Market Cap | $42.22B | $7.32B |
Sector | Health | Technology |
52-Week High | $157.20 | $29.15 |
52-Week Low | $110.24 | $14.55 |
Enterprise Value | $43.77B | $7.20B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.23, near its consensus price target of $154.90, with a slight 0.33% decline over 24 hours. The stock shows strong fundamentals, including a 19.55% net income margin and robust ROE of 21.33%, while technical indicators signal a bullish trend despite overbought RSI levels. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, reinforcing growth in biopharma services.
Outlook remains positive with 77.5% analyst buy ratings, but risks include high valuation multiples (P/E 30.02) and dependence on healthcare spending. Earnings beat in Q1 2026 supports upside, though Q2 2026 results due August 26 are critical for momentum. Institutional accumulation, like Ashton Thomas Securities' 47.1% stake increase in Q2 2026, underscores confidence.
ZETA trades at $28.55, up 3.67% today, near its consensus price target of $30.44. The stock shows bullish technical signals with strong moving average support and resistance at $30. Fundamentally, revenue grew to $1.3B in 2025 with a gross margin of 59.48%, though net income remains negative. Recent Q2 2026 earnings beat estimates with 44% revenue growth, marking the 20th consecutive beat-and-raise quarter, driven by AI adoption and partnerships.
Outlook is positive with analyst consensus at Buy (73%) and a $30.44 target, but risks include rich valuation (P/S 4.35, EV/EBITDA 95.89) and execution challenges in integrating AI growth. Investors face volatility from high RSI levels, yet sustained earnings momentum and institutional accumulation support upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
